Trevi Therapeutics, Inc. (TRVI) Company Overview

What does Trevi Therapeutics do?

Trevi Therapeutics, Inc. is a Nasdaq-listed, clinical-stage biopharmaceutical company centered on one investigational asset: Haduvio, the proposed trade name for oral extended-release nalbuphine. The company is developing it for chronic cough associated with idiopathic pulmonary fibrosis, chronic cough associated with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is not approved in any indication, so Trevi has no product revenue and should be analyzed as a development-stage pipeline rather than as an operating pharmaceutical franchise.

Why does this small company matter?

The strategic case rests on a large unmet need and a differentiated mechanism. Trevi describes Haduvio as a kappa-opioid receptor agonist and mu-opioid receptor antagonist that acts on the cough reflex arc both centrally and peripherally. That is intended to address cough hypersensitivity rather than merely one upstream trigger. The company’s official Haduvio overview explains this KAMA mechanism and its potential relevance across different chronic-cough disorders.

How does Trevi Therapeutics make money?

Trevi does not currently make money from customers. Since inception, it has financed operations mainly through equity offerings and invested the proceeds in clinical trials, regulatory studies, intellectual property, and corporate infrastructure. Its business model is therefore a conversion model: capital is converted into clinical evidence; evidence may support regulatory approval; approval could then create product sales, licensing income, or partnership economics.

What would future revenue look like?

If approved, Haduvio would most likely generate specialty-pharmaceutical revenue tied to treated patients, net price, adherence, duration of therapy, and gross-to-net deductions. Trevi’s first commercial focus is IPF-related chronic cough, where pulmonologists already manage the underlying disease and where no FDA-approved cough therapy exists. Non-IPF ILD and RCC could expand the addressable population, but each indication requires separate development, regulatory evidence, and payer positioning.

How does the license affect economics?

Trevi holds an exclusive worldwide sublicensable license from Keenova Therapeutics for nalbuphine hydrochloride formulations, including Haduvio. The 2025 Form 10-K discloses a $0.3 million milestone after successful completion of the first Phase 3 trial and $0.8 million upon U.S. marketing approval, plus royalties on net sales and a low-to-mid double-digit share of certain sublicense income. These obligations are manageable relative to a successful launch, but they mean Trevi does not retain the full economics of Haduvio.

Which clinical programs and trial readouts matter most?

Trevi’s pipeline is not three unrelated products; it is one pharmacologic platform tested in three patient groups. That creates operating leverage if Haduvio’s mechanism generalizes, but it also creates correlated risk. The IPF-related chronic-cough program is the value anchor because it has completed Phase 2b, received End-of-Phase 2 alignment from the FDA, and advanced to a two-trial pivotal plan.

What did CORAL establish?

The 165-patient Phase 2b CORAL trial in IPF-related chronic cough met its primary endpoint at Week 6. Relative reductions from baseline in 24-hour cough frequency were 47.9% for 27 mg twice daily, 53.4% for 54 mg twice daily, and 60.2% for 108 mg twice daily, compared with 16.9% for placebo. The dose response and objective cough-monitor endpoint gave regulators a concrete basis for Phase 3 design, although Phase 2 success never guarantees pivotal replication.

Why are OCEAN-1 and OCEAN-2 designed differently?

Trevi’s June 2026 corporate presentation labels the pivotal studies OCEAN-1 and OCEAN-2. The longer study is designed to provide a 24-week efficacy endpoint plus 52-week safety exposure, while the shorter study tests efficacy at 12 weeks. Parallel execution can compress calendar time, but it raises simultaneous enrollment, site-management, drug-supply, and cash-burn demands.

What does Trevi Therapeutics’ latest quarter show?

The latest official reporting package is the quarter ended March 31, 2026. It shows a company moving from data generation into parallel late-stage execution. R&D rose because Trevi was preparing the Phase 3 IPF program, the Phase 2b RCC study, and NDA-supportive Phase 1 work. G&A also increased as legal, intellectual-property, stock-compensation, and personnel costs expanded. The company’s Q1 2026 earnings release emphasizes that the April financing extended management’s estimated runway into 2030.

How is the expense base changing?

The mix remains research-heavy, which is appropriate for a clinical-stage company. The more important question is not whether costs rise, but whether rising costs buy timely enrollment, clean execution, and decision-quality data. The Q1 2026 Form 10-Q states that existing resources are expected to support the IPF program potentially through FDA approval, but exclude commercial-launch spending.

What turning points shaped Trevi’s current strategy?

Trevi’s history is best understood as a sequence of narrowing and validation. The company began with broad rights to nalbuphine formulations, explored several indications, and ultimately concentrated resources on chronic cough after clinical evidence strengthened the case. That focus now defines both the opportunity and the risk.

1. 2011
   Trevi was founded and secured the exclusive worldwide nalbuphine license. This transaction remains the legal foundation of the Haduvio program and creates continuing royalty and milestone obligations.
2. 2019
   The company completed its Nasdaq initial public offering, giving Trevi recurring access to public equity capital for long-duration clinical development.
3. Q4 2023
   Trevi initiated the CORAL Phase 2b IPF-related cough trial and the RIVER Phase 2a RCC trial, creating two independent tests of the same cough-hypersensitivity thesis.
4. March 2025
   Positive RIVER results supported activity in RCC and reduced dependence on the IPF indication alone, although the RCC program still required a larger Phase 2b study.
5. June 2025
   CORAL met its primary endpoint across all three doses, making 54 mg twice daily the pivotal-program dose and shifting the company’s center of gravity toward Phase 3 execution.
6. March–April 2026
   FDA End-of-Phase 2 alignment clarified the pivotal path, and a $173.4M gross common-stock offering supplied approximately $162M of net proceeds to fund it.

What changed after FDA alignment?

The March 2026 End-of-Phase 2 update moved Trevi from an open-ended development story to a defined two-trial program with agreed supporting studies. That does not eliminate regulatory risk, but it narrows the key questions to execution, efficacy replication, safety exposure, and the completeness of the NDA package.

What gives Haduvio a potential competitive advantage?

Trevi does not yet possess a commercial moat. It has a potential moat composed of mechanism, clinical evidence, regulatory positioning, and intellectual property. Each element must survive Phase 3 and commercialization before it becomes durable.

Why is the mechanism differentiated?

Haduvio targets both central and peripheral components of cough hypersensitivity through kappa agonism and mu antagonism. Competing approaches often focus on peripheral sensory targets such as P2X3. A broad mechanism could support activity across distinct cough etiologies, as suggested by positive IPF and RCC studies. Conversely, central activity can also create tolerability trade-offs, including somnolence, dizziness, nausea, constipation, headache, and fatigue observed in prior trials.

How strong is the intellectual-property position?

The June 2026 presentation describes an issued U.S. method-of-use patent and a granted European patent for IPF-related chronic cough expected to expire in 2039, plus a U.S. patent covering dosing in hepatic impairment expected to expire in 2041. Additional label-driven applications could extend protection later, but pending claims are not equivalent to issued patents. The older licensed formulation patents expire sooner, so the commercial defense increasingly depends on Trevi’s own method-of-use, dosing, clinical, and regulatory package.

Who competes with Trevi Therapeutics?

Competition differs by indication. In IPF-related chronic cough, Trevi’s most important advantage is the absence of an FDA-approved cough-specific therapy and the termination of a competing TRPA1 program disclosed in Trevi’s 2025 filing. In RCC, competition is more active because large pharmaceutical companies and private biotechs are pursuing alternative sensory-pathway mechanisms.

What will determine market position?

Trevi’s official competition disclosure identifies efficacy, safety, health-economic benefit, convenience, price, reimbursement, and speed to approval as the relevant dimensions. For IPF, specialist concentration may support efficient launch economics. For RCC, Trevi would need broader awareness, stronger differentiation from P2X3 agents, and disciplined management of opioid-associated perceptions even though nalbuphine is not currently scheduled by the U.S. DEA.

How financially strong is Trevi Therapeutics?

Trevi’s balance sheet is unusually well funded for its size after the April 2026 offering. At March 31, 2026, before that transaction, cash plus marketable securities totaled $171.8 million, current liabilities were $7.1 million, total liabilities were $7.5 million, and stockholders’ equity was $172.1 million. The financing then added approximately $162 million of net proceeds. The company has little physical plant; its capital intensity sits in trial commitments, manufacturing, and outsourced services rather than property and equipment.

How did the April 2026 offering change the story?

The offering closing announcement removed a major near-term financing overhang and improved negotiating leverage with vendors or potential partners. It also diluted existing holders and increased the importance of per-share valuation rather than enterprise value alone.

Who owns Trevi Therapeutics stock, and why does it matter?

Trevi has one-share-one-vote common stock rather than a founder-controlled dual-class structure. However, the investor base includes concentrated life-sciences funds, and one director’s affiliated holdings create meaningful alignment and influence. Ownership percentages in the 2026 proxy are measured as of April 6, 2026, before the April offering, so they should not be treated as current post-offering percentages.

What does governance signal?

Founder Jennifer Good has led Trevi since 2011 and owned 1.99% beneficially in the proxy. The board determined that every director except the CEO was independent under Nasdaq rules, and its audit, compensation, and nominating committees consisted of independent directors. The 2026 proxy statement therefore depicts founder continuity with conventional public-company oversight rather than absolute founder control.

What opportunities and risks could change Trevi’s outlook?

Where is the upside concentrated?

The largest opportunity is a successful IPF program that establishes Haduvio as the first FDA-approved therapy specifically for IPF-related chronic cough. Trevi’s Q1 materials estimate about 140,000 U.S. IPF patients, with roughly two-thirds experiencing uncontrolled chronic cough. Non-IPF ILD adds an estimated 228,000 U.S. patients, with 50%–60% affected by uncontrolled cough, while RCC represents an estimated 2–3 million U.S. adults. These are management-sourced epidemiology estimates, not guaranteed treated populations.

Which risks are most material?

What matters most for Trevi’s valuation and final takeaway?

Traditional revenue multiples are not useful because Trevi has no product sales. A sensible framework is risk-adjusted net present value: model each indication separately, assign a probability of technical and regulatory success, forecast launch timing, eligible patients, penetration, net price, treatment duration, gross margin, royalties, selling expense, tax, and reinvestment, then subtract corporate costs and adjust for cash and future dilution.

What should students and investors watch next?

• Confirmation that both pivotal IPF trials are active and enrolling on schedule.
• The RCC Phase 2b sample-size re-estimation and any protocol changes.
• Start and design details for the non-IPF ILD study after regulatory review.
• Quarterly R&D growth, operating cash use, and updated runway guidance.
• New patent issuances, especially indication and label-driven claims.
• Commercial-readiness spending, partnering decisions, and any change in the fully diluted share count.